NASDAQ:XLRN - Acceleron Pharma Stock Price, Forecast & News

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma Inc (NASDAQ:XLRN) posted its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.83) by $0.03. The biopharmaceutical company earned $4.20 million during the quarter, compared to analyst estimates of $4.44 million. Acceleron Pharma had a negative net margin of 353.57% and a negative return on equity of 30.79%. Acceleron Pharma's revenue was up 27.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.63) earnings per share. View Acceleron Pharma's Earnings History.

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Acceleron Pharma.

Acceleron Pharma will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

14 brokerages have issued 1 year target prices for Acceleron Pharma's shares. Their forecasts range from $45.00 to $138.00. On average, they expect Acceleron Pharma's stock price to reach $94.31 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

Press coverage about XLRN stock has trended extremely negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Acceleron Pharma earned a daily sentiment score of -4.2 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Acceleron Pharma.

Some companies that are related to Acceleron Pharma include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Crispr Therapeutics (CRSP) and Momenta Pharmaceuticals (MNTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Gilead Sciences (GILD), Incyte (INCY), NVIDIA (NVDA), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Intel (INTC), LogicBio Therapeutics (LOGC) and Bausch Health Companies (BHC).

Acceleron Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Farallon Capital Management LLC (3.77%), State Street Corp (2.75%), Westfield Capital Management Co. LP (2.17%), Janus Henderson Group PLC (2.14%) and Eagle Asset Management Inc. (1.72%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops and Sujay Kango. View Institutional Ownership Trends for Acceleron Pharma.

XLRN stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Sofinnova Investments Inc., Janus Henderson Group PLC, Credit Suisse AG, AXA, Westfield Capital Management Co. LP, Candriam Luxembourg S.C.A. and Alliancebernstein L.P.. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View Insider Buying and Selling for Acceleron Pharma.

XLRN stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Great Lakes Advisors LLC, Aviva PLC, Artisan Partners Limited Partnership, State Street Corp, Cubist Systematic Strategies LLC and UBS Asset Management Americas Inc.. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XLRN stock can currently be purchased for approximately $94.13.

Acceleron Pharma has a market capitalization of $5.00 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.

The official website for Acceleron Pharma is http://www.acceleronpharma.com/.

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]